is Associated with Clofazimine Resistance in

Overview

Journal Microbiol Spectr

Specialty Microbiology

Date 2023 Aug 24

PMID 37615440

Authors

Lei Zhang

Ye Zhang

Yuanyuan Li

Fengmin Huo

Xi Chen

Hui Zhu

Shaochen Guo

Lei Fu

Bin Wang

Yu Lu

Affiliations

Soon will be listed here.

Abstract

Clofazimine (CFZ) has been repurposed for treating tuberculosis (TB), especially multidrug-resistant tuberculosis (MDR-TB). However, the mechanisms of resistance to clofazimine are poorly understood. We previously reported a mutation located in the intergenic region of that was linked to resistance to CFZ and demonstrated that an knockout resulted in an increased minimum inhibitory concentration (MIC) of CFZ. The current study aims to go back and describe in detail how the mutation was identified and further explore its association with CFZ resistance by testing additional 30 isolates. We investigated MICs of clofazimine against 100 clinical strains isolated from MDR-TB patients by microplate alamarBlue assay. Whole-genome sequencing (WGS) was performed on 11 clofazimine-resistant and 7 clofazimine-susceptible strains, including H37Rv. Among the 11 clofazimine-resistant mutants subjected to WGS, the rate of mutation in the intergenic region of the gene was 55% (6/11) in clofazimine-resistant strains. Among another 30 clofazimine-resistant clinical isolates, 27 had mutations in the intergenic region of the gene. A mutation in the gene associated with clofazimine resistance was identified, which shed light on the mechanisms of action and resistance of clofazimine. IMPORTANCE Tuberculosis (TB) is an infectious disease caused by the bacterium , especially the emergence of multidrug-resistant tuberculosis (MDR-TB) brings great distress to humans. Clofazimine (CFZ) plays an important role in the treatment of MDR-TB. To understand the underlying mechanism of clofazimine resistance better, in this study, we review and detail the findings of the mutation of intergenic region of and find additional evidence that this mutation is related to clofazimine resistance in 30 additional isolates. The significance of our research is to contribute to a comprehensive understanding of clofazimine-resistant mechanisms, which is critical for reducing the emergence of resistance and for anti-TB drug discovery.

References

Ismail N, Omar S, Joseph L, Govender N, Blows L, Ismail F . Defining Bedaquiline Susceptibility, Resistance, Cross-Resistance and Associated Genetic Determinants: A Retrospective Cohort Study. EBioMedicine. 2018; 28:136-142. PMC: 5835552. DOI: 10.1016/j.ebiom.2018.01.005. View

BARRY V, BELTON J, CONALTY M, DENNENY J, EDWARD D, OSullivan J . A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature. 1957; 179(4568):1013-5. DOI: 10.1038/1791013a0. View

Xu J, Wang B, Hu M, Huo F, Guo S, Jing W . Primary Clofazimine and Bedaquiline Resistance among Isolates from Patients with Multidrug-Resistant Tuberculosis. Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444180. DOI: 10.1128/AAC.00239-17. View

Somoskovi A, Bruderer V, Homke R, Bloemberg G, Bottger E . A mutation associated with clofazimine and bedaquiline cross-resistance in MDR-TB following bedaquiline treatment. Eur Respir J. 2014; 45(2):554-7. DOI: 10.1183/09031936.00142914. View

Hu Y, Morichaud Z, Chen S, Leonetti J, Brodolin K . Mycobacterium tuberculosis RbpA protein is a new type of transcriptional activator that stabilizes the σ A-containing RNA polymerase holoenzyme. Nucleic Acids Res. 2012; 40(14):6547-57. PMC: 3413145. DOI: 10.1093/nar/gks346. View

Islam M, Hameed H, Mugweru J, Chhotaray C, Wang C, Tan Y . Drug resistance mechanisms and novel drug targets for tuberculosis therapy. J Genet Genomics. 2017; 44(1):21-37. DOI: 10.1016/j.jgg.2016.10.002. View

Chen X, He G, Wang S, Lin S, Chen J, Zhang W . Evaluation of Whole-Genome Sequence Method to Diagnose Resistance of 13 Anti-tuberculosis Drugs and Characterize Resistance Genes in Clinical Multi-Drug Resistance Isolates From China. Front Microbiol. 2019; 10:1741. PMC: 6685394. DOI: 10.3389/fmicb.2019.01741. View

Lu Y, Zheng M, Wang B, Fu L, Zhao W, Li P . Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation. Antimicrob Agents Chemother. 2011; 55(11):5185-93. PMC: 3195009. DOI: 10.1128/AAC.00699-11. View

Cholo M, Steel H, Fourie P, Germishuizen W, Anderson R . Clofazimine: current status and future prospects. J Antimicrob Chemother. 2011; 67(2):290-8. DOI: 10.1093/jac/dkr444. View

10.

Xie J, Chen Y, Cai G, Cai R, Hu Z, Wang H . Tree Visualization By One Table (tvBOT): a web application for visualizing, modifying and annotating phylogenetic trees. Nucleic Acids Res. 2023; 51(W1):W587-W592. PMC: 10320113. DOI: 10.1093/nar/gkad359. View

11.

Almeida D, Ioerger T, Tyagi S, Li S, Mdluli K, Andries K . Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016; 60(8):4590-9. PMC: 4958187. DOI: 10.1128/AAC.00753-16. View

12.

Tang S, Yao L, Hao X, Liu Y, Zeng L, Liu G . Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China. Clin Infect Dis. 2015; 60(9):1361-7. DOI: 10.1093/cid/civ027. View

13.

Saikolappan S, Das K, Dhandayuthapani S . Inactivation of the organic hydroperoxide stress resistance regulator OhrR enhances resistance to oxidative stress and isoniazid in Mycobacterium smegmatis. J Bacteriol. 2014; 197(1):51-62. PMC: 4288688. DOI: 10.1128/JB.02252-14. View

14.

Zheng H, He W, Jiao W, Xia H, Sun L, Wang S . Molecular characterization of multidrug-resistant tuberculosis against levofloxacin, moxifloxacin, bedaquiline, linezolid, clofazimine, and delamanid in southwest of China. BMC Infect Dis. 2021; 21(1):330. PMC: 8028109. DOI: 10.1186/s12879-021-06024-8. View

15.

Zhang S, Chen J, Cui P, Shi W, Zhang W, Zhang Y . Identification of novel mutations associated with clofazimine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2015; 70(9):2507-10. PMC: 4539095. DOI: 10.1093/jac/dkv150. View

16.

Merker M, Kohl T, Barilar I, Andres S, Fowler P, Chryssanthou E . Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020; 12(1):27. PMC: 7060619. DOI: 10.1186/s13073-020-00726-5. View

17.

Yano T, Kassovska-Bratinova S, Teh J, Winkler J, Sullivan K, Isaacs A . Reduction of clofazimine by mycobacterial type 2 NADH:quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J Biol Chem. 2011; 286(12):10276-87. PMC: 3060482. DOI: 10.1074/jbc.M110.200501. View

18.

Coll F, McNerney R, Guerra-Assuncao J, Glynn J, Perdigao J, Viveiros M . A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014; 5:4812. PMC: 4166679. DOI: 10.1038/ncomms5812. View

19.

Du Y, Qiu C, Chen X, Wang J, Jing W, Pan H . Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China. Clin Infect Dis. 2019; 71(4):1047-1054. DOI: 10.1093/cid/ciz915. View

20.

Villellas C, Coeck N, Meehan C, Lounis N, de Jong B, Rigouts L . Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline. J Antimicrob Chemother. 2016; 72(3):684-690. PMC: 5400087. DOI: 10.1093/jac/dkw502. View